Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adjuvant Holdings Co's revenue for the
six
months ended in Mar. 2026 was 円1,958 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,814 Mil.
Adjuvant Holdings Co's Revenue per Share for the
six
months ended in Mar. 2026 was 円244.71.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円476.33.
Warning Sign:
Adjuvant Holdings Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Adjuvant Holdings Co was -6.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -4.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Adjuvant Holdings Co's highest 3-Year average Revenue per Share Growth Rate was 5.40% per year. The lowest was -9.50% per year. And the median was -2.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Adjuvant Holdings Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adjuvant Holdings Co Revenue vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Adjuvant Holdings Co's Revenue distribution charts can be found below:
* The bar in red indicates where Adjuvant Holdings Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円3,814 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adjuvant Holdings Co (TSE:4929) has a Revenue of 円3,814 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Adjuvant Holdings Co and its competitors.
Is Adjuvant Holdings Co's Revenue too high?
Adjuvant Holdings Co's current Revenue is 円3,814 Mil. Overall, Adjuvant Holdings Co has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Adjuvant Holdings Co's Revenue compare to PG and CL?
Adjuvant Holdings Co's Revenue of 円3,814 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Consumer Packaged Goods company?
A good Revenue depends on the Consumer Packaged Goods industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Adjuvant Holdings Co and its competitors. Adjuvant Holdings Co's current Revenue is 円3,814 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adjuvant Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Adjuvant Holdings Co (TSE:4929) is currently considered Fairly Valued. The stock's GF Value™ is 円732.52, compared to a current price of 円736.00 — trading 0.5% above its estimated fair value. The current Revenue is 円3,814 Mil. Adjuvant Holdings Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Adjuvant Holdings Co (TSE:4929), the current Revenue is 円3,814 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adjuvant Holdings Co (TSE:4929) Overvalued in 2026?
Based on GuruFocus' analysis, Adjuvant Holdings Co stock appears to be overvalued.
The current stock price of 円736.00 is trading 0.5% above its estimated GF Value™ of 円732.52.
GuruFocus considers Adjuvant Holdings Co to be Fairly Valued.
Key valuation signals for TSE:4929:
Revenue: 円3,814 Mil
GF Value™: 円732.52 vs. price of 円736.00 (0.5% above fair value)
No single metric tells the full story. See the TSE:4929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adjuvant Holdings Co Ltd, formerly Adjuvant Cosme Japan Co Ltd is engaged in the research, development, production, and sale of cosmetics in Japan. It offers skin care products, including cleansing products, facial cleansers, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeup, and body care products among other products.
59GF Score
Get the complete analysis for TSE:4929
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4929 has been successfully added to your 
